Genelux enters $100M at-the-market equity offering agreement with TD Cowen

GENELUX Corp

Sales Agreement with TD Cowen allows offering of common stock up to $100M aggregate.
TD Cowen receives up to 3.0% commission on gross proceeds from sales.
Proceeds for general corporate purposes, including R&D, clinical trials, and capex.
Company has no obligation to sell shares; may suspend at any time.
Shares offered via at-the-market program on Nasdaq or negotiated transactions.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

GENELUX Corp entered into Sales Agreement with TD Securities (USA) LLC valued at up to $100,000,000 (effective 2026-03-19).

Action: entry
Agreement: atm program
Counterparty: TD Securities (USA) LLC
Value: up to $100,000,000
Effective: 2026-03-19

Exact text from the filing

On March 19, 2026, Genelux Corporation (the “Company”) entered into a Sales Agreement (the “Sales Agreement”) with TD Securities (USA) LLC (“TD Cowen”), pursuant to which the Company may, from time to time, offer and sell shares of the Company’s common stock, par value $0.001 per share (the “Placement Shares”), having an aggregate offering price of up to $100,000,000, through TD Cowen, acting as the Company’s sales agent and/or principal.

View on SEC.gov

299 material agreements filed in the last 30 days. Browse all material agreements →

GENELUX Corp filing history →

Source: SEC EDGAR

accession 0001493152-26-011649

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.